Beryl Drugs Faces Challenges Amid Shift to Mildly Bearish Outlook and Volatility
Beryl Drugs has recently adjusted its evaluation score, reflecting a change in technical trends. The company has faced significant challenges over the past year, with a notable decline in stock performance and considerable volatility. Key financial metrics indicate weak long-term fundamentals and constrained debt servicing capabilities.
Beryl Drugs, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation score. This revision reflects a shift in technical trends, moving from a bearish stance to a mildly bearish outlook. The stock's current price stands at 19.45, slightly below its previous close of 19.50. Over the past year, Beryl Drugs has faced significant challenges, with a return of -46.20%, contrasting sharply with the broader market's performance. The company's 52-week high was recorded at 46.00, while the low reached 17.35, indicating considerable volatility.
Key financial metrics reveal a weak long-term fundamental strength, highlighted by an average Return on Capital Employed (ROCE) of 7.27%. Additionally, the company's net sales growth has been modest at an annual rate of 11.58%, with operating profit growth at 13.70% over the last five years. The ability to service debt appears constrained, as evidenced by a low EBIT to Interest ratio of 0.82.
Overall, Beryl Drugs is navigating a challenging landscape, with technical indicators suggesting a cautious approach.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
